7Baggers

ADMA Biologics, Inc
(NASDAQ:ADMA) 

ADMA stock logo

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of pr...

Founded: 2007
Full Time Employees: 313
CEO: Adam Grossman  
Sector: Healthcare
Industry: Biotechnology
Pharmaceuticals
Share this website to your friends
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
    Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31 
                                                             
      revenues
    		114,493,000 139,163,000 134,224,000 121,984,000 114,802,000 117,549,000 119,839,000 107,191,000 81,875,000 73,903,677 67,274,598 60,123,191 56,913,534                                        792,935 523,284 360,338 230,096 4,400 
      yoy
    		-0.27% 18.39% 12.00% 13.80% 40.22% 59.06% 78.13% 78.29% 43.86%                                            17921.25%     
      qoq
    		-17.73% 3.68% 10.03% 6.26% -2.34% -1.91% 11.80% 30.92% 10.79% 9.85% 11.89% 5.64%                                         51.53% 45.22% 56.60% 5129.45%  
      cost of product revenue
    		33,743,000 50,347,000 58,598,000 54,757,000 53,705,000 54,216,000 60,180,000 49,738,000 42,767,000 42,817,255 42,622,013 43,433,188 40,400,544 35,804,379 31,433,496 26,135,614 25,441,046 22,871,382 20,295,213 18,832,624 17,770,122 19,111,107 11,855,464 13,495,629 16,829,226 11,691,603 7,916,220 10,491,236 9,405,179 11,142,116 9,164,109 9,645,662 12,242,748 11,922,899 11,291,116 4,334,019 1,616,287 2,014,328 1,735,771 1,344,241 1,266,421 1,502,735 1,112,782 786,315 909,629 956,841 867,681 940,815 977,030 282,389 726,245 485,761      
      gross profit
    		80,750,000 88,816,000 75,626,000 67,227,000 61,097,000 63,333,000 59,659,000 57,453,000 39,108,000 31,086,422 24,652,585 16,690,003 16,512,990 14,177,076 9,656,641 7,769,393 3,662,047                                    263,889 142,989 215,647 88,226  
      yoy
    		32.17% 40.24% 26.76% 17.01% 56.23% 103.73% 142.00% 244.24% 136.83% 119.27% 155.29% 114.82% 350.92%                                             
      qoq
    		-9.08% 17.44% 12.49% 10.03% -3.53% 6.16% 3.84% 46.91% 25.80% 26.10% 47.71% 1.07% 16.48% 46.81% 24.29% 112.16%                                     84.55% -33.69% 144.43%   
      gross margin %
    		70.53% 63.82% 56.34% 55.11% 53.22% 53.88% 49.78% 53.60% 47.77% 42.06% 36.64% 27.76% 29.01% Infinity% Infinity% Infinity% Infinity% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% 33.28% 27.33% 59.85% 38.34% 0% 
      operating expenses:
    		                                                         
      research and development
    		2,597,000 1,376,000 1,528,000 1,031,000 826,000 391,000 412,000 560,000 450,000 445,486 595,903 1,403,260 855,351 1,074,320 1,041,947 873,386 624,111 728,988 770,557 1,158,866 987,649 1,013,464 1,708,391 1,656,420 1,528,738 464,823 491,404 516,986 870,635 -144,920 1,317,234 1,472,100 1,281,706 1,864,382 1,814,069 1,358,409 1,192,727 583,374 1,677,263 3,399,889 2,027,712 1,996,808 2,111,505 1,505,909 1,401,723 1,919,719 1,482,929 1,783,909 4,330,457 2,956,153 1,408,990 3,470,350 1,467,584     
      plasma center operating expenses
    		1,062,000 1,126,000 1,272,000 1,152,000 1,286,000 1,277,000 1,021,000 942,000 1,005,000 685,215 466,898 1,333,424 1,780,463 5,087,571 4,859,450 3,921,486 3,974,589 4,096,833 3,146,221 2,803,326 2,242,343 1,572,607 1,218,898 877,902 500,644 464,131 456,899 594,113 654,486 2,260,379 1,973,338 1,738,128                      419,103 489,300 379,168 461,493 
      amortization of intangible assets
    		55,000 51,000 38,000 32,000 25,000 25,000 28,000 142,000 193,000 187,486 178,838 178,838 178,838 178,839 178,838 178,838 178,838 178,839 178,838 178,838 178,838 178,839 178,838 178,838 178,838 211,234 211,235 211,234 211,235                             
      gain on sale of plasma centers
    		-7,980,000                                                         
      selling, general and administrative
    		26,742,000 23,512,000 21,776,000 22,214,000 24,079,000 23,317,000 18,560,000 16,608,000 15,639,000 15,534,999 14,725,787 14,247,558 14,511,656 13,894,888 12,893,139 11,970,422 13,699,575 11,698,009 10,726,797 10,438,168 10,033,915 9,300,359 9,115,744 8,702,630 7,932,084 7,032,067 7,197,173 6,086,047 5,595,470 7,135,275 5,355,794 5,006,807 5,005,046 5,184,337 4,195,464 4,435,650                      
      total operating expenses
    		22,476,000 26,065,000 24,614,000 24,429,000 26,216,000 25,010,000 20,021,000 18,252,000 17,287,000 16,853,186 15,967,426 17,163,080 17,326,308 20,235,618 18,973,374 16,944,132 18,477,113 -40,195,290 35,117,626 33,411,822 31,212,867 31,176,376 24,077,335 24,911,419 26,969,530 19,863,858 16,272,931 17,899,616 16,737,005 20,604,084 18,021,710 18,073,931 20,574,509 22,546,242 19,157,171 11,801,269 8,565,874 7,271,681 6,674,735 7,762,594 6,282,422 6,642,848 6,516,611 4,826,538 4,705,443 5,197,682 4,404,212 5,087,639 7,244,545 4,942,275 3,638,312 5,586,397 3,413,978 2,383,296 3,464,467 1,294,766  
      income from operations
    		58,274,000 62,751,000 51,012,000 42,798,000 34,881,000 38,323,000 39,638,000 39,201,000 21,821,000 14,233,236 8,685,159 -473,077 -813,318 -6,058,542 -9,316,733 -9,174,739 -14,815,066 -13,191,184 -14,437,076 -15,581,232 -15,164,249 -17,220,289 -13,800,977 -17,123,825 -16,769,786 -7,826,809 -9,050,428 -11,338,674 -13,208,416 -16,547,660 -13,791,400 -13,417,381 -16,532,503 -10,543,365 -14,427,760 -8,401,868 -5,937,003 -3,944,137 -3,736,872 -5,490,850 -4,158,536 -4,130,667 -4,664,198 -3,516,605 -3,202,337 -3,708,945 -3,038,282 -3,587,320 -5,683,986 -4,518,244 -2,530,971 -4,843,127 -3,150,089 -2,240,307 -3,248,820 -1,206,540 -1,213,502 
      yoy
    		67.07% 63.74% 28.69% 9.18% 59.85% 169.25% 356.39% -8386.39% -2782.96% -334.93% -193.22% -94.84% -94.51% -54.07% -35.47% -41.12% -2.30% -23.40% 4.61% -9.01% -9.57% 120.02% 52.49% 51.02% 26.96% -52.70% -34.38% -15.49% -20.11% 56.95% -4.41% 59.70% 178.47% 167.32% 286.09% 53.02% 42.77% -4.52% -19.88% 56.14% 29.86% 11.37% 53.51% -1.97% -43.66% -17.91% 20.04% -25.93% 80.44% 101.68% -22.10% 301.41% 159.59%     
      qoq
    		-7.13% 23.01% 19.19% 22.70% -8.98% -3.32% 1.11% 79.65% 53.31% 63.88% -1935.89% -41.83% -86.58% -34.97% 1.55% -38.07% 12.31% -8.63% -7.34% 2.75% -11.94% 24.78% -19.40% 2.11% 114.26% -13.52% -20.18% -14.16% -20.18% 19.99% 2.79% -18.84% 56.80% -26.92% 71.72% 41.52% 50.53% 5.55% -31.94% 32.04% 0.67% -11.44% 32.63% 9.81% -13.66% 22.07% -15.30% -36.89% 25.80% 78.52% -47.74% 53.75% 40.61% -31.04% 169.27% -0.57%  
      operating margin %
    		50.90% 45.09% 38.01% 35.08% 30.38% 32.60% 33.08% 36.57% 26.65% 19.26% 12.91% -0.79% -1.43% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -397.27% -428.12% -901.60% -524.36% -27579.59% 
      other income:
    		                                                         
      interest and other income
    		1,093,000                     67,160.75 1,164 19,411 248,068 154,775.75 281,896 209,808 127,399                             
      interest expense
    		-2,100,000 -1,371,000 -1,675,000   -2,879,000 -3,499,000 -3,783,000 -3,769,000 -6,214,856 -6,397,553 -6,299,107 -6,115,484 -5,736,954 -5,580,366 -4,573,015 -3,389,038 -3,315,724 -3,298,680 -3,246,680 -3,195,750 -3,109,469 -3,091,200 -3,067,306 -2,717,091 -2,730,890 -2,649,404 -2,072,578 -1,540,507 -1,437,968 -1,402,475 -1,359,188 -1,323,152 -1,241,865 -782,969 -642,485 -618,528 -628,158 -605,972 -537,998 -467,441 -463,938 -449,328 -453,411 -476,040 -381,281 -335,299 -342,750 -226,885 -167,651 -162,934 -158,844 -128,796   -3,098 -8,494 
      other expense
    		-140,000 -48,750 -21,000   -86,000 -56,000 -16,000 -35,000 -101,362 -145,827 -12,827 -26,984 -438,447 -9,641 -19,421 -166,880 9,564,066 -3,275,878 -83,317 -42,001 -89,296 -26,440 -6,371 -6,421 -185,014 -20,523 -1,873,198  -112,565 -17,191 -1,330,450 -1,289,639 -2,439,437 -774,955 -634,627  -614,971 -594,367 -521,485 -453,933 -451,986 -438,226               
      other income
    		-1,147,000                 -26,693 18,546      -2,475,444   -10,428 -11,357   -4,332 6,967       4,496      -235,054.5 -346,407     82,497  367.75 3,073   
      income before income taxes
    		57,127,000 61,595,000 47,515,000 40,097,000 33,450,000 34,713,000 36,749,000 35,851,000 18,401,000                                         -2,706,509.5 -2,688,947 -4,895,444 -3,241,647 -2,251,537 -3,245,747 -1,206,715 -1,214,929 
      provision for income taxes
    		11,799,000 5,877,500 11,087,000 5,878,000 6,546,000 1,306,000 840,000 3,789,000 595,000                                                 
      net income
    		45,328,000 49,379,000 36,428,000 34,219,000 26,904,000 111,896,000 35,909,000 32,062,000 17,806,000 -17,644,533 2,565,055 -6,370,707 -6,788,815 -12,231,683 -14,899,504 -13,764,906 -25,007,857 -16,649,420 -17,712,954 -18,905,303 -18,379,941 -19,407,774 -16,917,453 -20,178,091 -19,245,230 -10,561,031 -11,438,459 -13,211,872 -13,067,955 -18,037,987 -15,135,485 -14,747,831 -17,822,142 -12,982,802 -15,202,715 -9,036,495 -6,536,963 -4,559,108 -4,331,239 -6,012,335 -4,612,469 -4,582,653 -5,102,424 -4,679,318 -3,605,535 -3,563,357 -3,384,689 -3,961,245 -5,903,872 -4,701,208 -2,688,947 -4,895,444 -3,241,647 -2,251,537 -3,245,747 -1,206,715 -597,314 
      yoy
    		68.48% -55.87% 1.45% 6.73% 51.10% -734.17% 1299.93% -603.27% -362.28% 44.25% -117.22% -53.72% -72.85% -26.53% -15.88% -27.19% 36.06% -14.21% 4.70% -6.31% -4.50% 83.77% 47.90% 52.73% 47.27% -41.45% -24.43% -10.41% -26.68% 38.94% -0.44% 63.20% 172.64% 184.77% 251.00% 50.30% 41.72% -0.51% -15.11% 28.49% 27.93% 28.60% 50.75% 18.13% -38.93% -24.20% 25.87% -19.08% 82.13% 108.80% -17.15% 305.68% 442.70%     
      qoq
    		-8.20% 35.55% 6.46% 27.19% -75.96% 211.61% 12.00% 80.06% -200.92% -787.88% -140.26% -6.16% -44.50% -17.91% 8.24% -44.96% 50.20% -6.00% -6.31% 2.86% -5.30% 14.72% -16.16% 4.85% 82.23% -7.67% -13.42% 1.10% -27.55% 19.18% 2.63% -17.25% 37.28% -14.60% 68.24% 38.24% 43.38% 5.26% -27.96% 30.35% 0.65% -10.19% 9.04% 29.78% 1.18% 5.28% -14.55% -32.90% 25.58% 74.83% -45.07% 51.02% 43.97% -30.63% 168.97% 102.02%  
      net income margin %
    		39.59% 35.48% 27.14% 28.05% 23.44% 95.19% 29.96% 29.91% 21.75% -23.88% 3.81% -10.60% -11.93% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -408.82% -430.27% -900.75% -524.44% -13575.32% 
      basic earnings per common share
    		190 210 150 140 110 480 150 140 80                                                 
      diluted earnings per common share
    		190 200 150 140 110 460 150 130 80                                                 
      weighted-average common shares outstanding:
    		                                                         
      basic
    		236,072,751,000 238,299,024,000 238,602,978,000 241,490,715,000 237,775,476,000 233,084,236,000 234,571,376,000 232,417,645,000 228,874,847,000  225,276,980                                               
      diluted
    		239,955,762,000 244,904,640,000 244,664,263,000 248,608,460,000 244,676,350,000 243,342,466,000 244,804,065,000 242,167,072,000 236,414,374,000  233,761,262                                               
      interest income
    		 487,000 376,000 400,000 608,000 598,000 666,000 449,000 384,000 612,449 423,276 414,304 166,971 2,260 7,236 2,269 33,068 2,291 4,256 5,926 22,059         60,206 75,581 33,070 26,546 8,610 8,014 7,858 18,568 13,187 11,605 12,017 13,508 11,952 11,102 9,795 4,982 5,305 3,508 3,625 1,779 1,965 2,145 3,003 510   2,923 7,067 
      loss on extinguishment of debt
    		 -834,000 -2,177,000              -6,669,941            -9,962,495               -719,097              
      basic income per common share
    		         -0.013 0.01                                               
      diluted income per common share
    		         -0.013 0.01                                               
      basic and diluted loss per common share
    		           -0.03 -0.03 -0.06 -0.08 -0.07 -0.13 -0.07 -0.13 -0.15 -0.16 -0.2 -0.19 -0.23 -0.26 -0.17 -0.19 -0.25 -0.28 -0.39 -0.33 -0.35 -0.39 -0.24 -0.59 -0.55                      
      weighted-average common shares outstanding:
    		                                                         
      basic and diluted
    		         223,977,315,000  222,683,393 221,921,750 197,874,895 196,383,935 196,353,185 195,871,932 139,578,538 133,770,147 127,416,126 115,661,937 86,145,052 87,698,258 86,347,467 73,781,507 54,348,136 59,317,830 52,206,204 46,353,068 45,188,899 46,350,392 42,712,168 45,317,042 22,896,042 25,790,805 16,427,054                      
      revenues:
    		                                                         
      product revenue
    		             49,945,746 41,054,429 33,869,298 29,067,385 26,347,158 20,644,842 17,794,881 16,012,910 13,920,378 10,240,650 7,751,885 10,164,036 12,001,340 7,186,795 6,525,233 3,492,881 4,020,715 4,194,602 4,620,841 4,006,298 4,967,168 4,693,703 3,363,692 2,593,163 3,291,835 2,902,155 2,236,035 2,088,178 2,453,793 1,821,229 1,291,044 1,484,217 1,469,848 1,347,041 1,481,430 1,541,670 405,142 1,088,452 736,974      
      license revenue
    		             35,709 35,708 35,709 35,708 35,709 35,708 35,709 35,708 35,709 35,708 35,709 35,708 35,709 35,708 35,709 35,708             17,240.5 31,184 18,889 18,889 18,889 18,889 18,889 18,889 18,889 18,889 6,296      
      total revenues
    		             49,981,455 41,090,137 33,905,007 29,103,093 26,382,867 20,680,550 17,830,590 16,048,618 13,956,087 10,276,358 7,787,594 10,199,744 12,037,049 7,222,503 6,560,942 3,528,589 4,056,424 4,230,310 4,656,550 4,042,006 12,002,877 4,729,411 3,399,401 2,628,871 3,327,544 2,937,863 2,271,744 2,123,886 2,512,181 1,852,413 1,309,933 1,503,106 1,488,737 1,365,930 1,500,319 1,560,559 424,031 1,107,341 743,270      
      gain on transfer of plasma center assets
    		                            11,527,421                             
      license and other revenue
    		                             26,781.25 35,708 35,709 35,708 26,781.25 35,708 35,709 35,708 35,709 35,708 35,709 35,708                 
      amortization of intangibles
    		                             158,426 211,235 211,234 211,235 887,825 273,828 73,021                      
      plasma centers
    		                                1,833,774 1,841,410 1,582,694 1,600,170 1,479,476 1,390,385 1,482,586 1,294,301 1,280,419 1,258,935 1,214,158 1,096,878  660,425 1,018,382 820,849          
      general and administrative
    		                                    4,277,384 3,283,594 1,779,115 1,724,163 1,707,870 1,884,370 2,078,166 1,437,436 1,345,997 1,111,994 1,035,220 1,542,066 1,134,589 998,635 845,301       
      other expense,net
    		                                    -599,960                     
      net loss per common share,
    		                                                         
      basic and diluted
    		                                    -0.51 -0.35 -0.34 -0.5 -0.43 -0.45 -0.48 -0.44 -0.37 -0.38 -0.36 -0.43 -0.64 -0.54 -0.46 -0.83      
      weighted-average shares
    		                                                         
      outstanding, basic and diluted
    		                                    12,886,741 247,131 12,886,741 12,121,500 10,710,587 -13,005 10,707,728  9,855,323  9,291,823 9,291,823 9,291,823 660,027 5,871,002 5,871,002      
      change in fair value of stock warrants
    		                                            67,860 -11,049 -14,616 -34,800 5,220 -17,278 2,813 21,027 36,728     
      total other expense
    		                                           -1,162,713 -403,198    -219,886         
      weighted-averageshares
    		                                                         
      outstanding, basic anddiluted
    		                                           10,705,573              
      plasma center
    		                                            1,048,094    802,469 705,098 657,776 539,994 515,288     
      net loss per common share
    		                                                         
      basic and diluted
    		                                    -0.51 -0.35 -0.34 -0.5 -0.43 -0.45 -0.48 -0.44 -0.37 -0.38 -0.36 -0.43 -0.64 -0.54 -0.46 -0.83      
      total other income
    		                                               -373,925  -182,964 -157,976 -52,317 -91,558   -175 -1,427 
      state income tax benefit
    		                                                        617,615 
      general and adminstrative
    		                                                   1,090,292 1,431,106     
      cost of sales
    		                                                    529,046 72,190.25 144,691 141,870  
      net loss per common share, basic and diluted
    		                                                    -0.55     
      weighted-average number of
    		                                                         
      common shares outstanding, basic and diluted
    		                                                    5,871,002     
      operating expenses
    		                                                         
      research and development expenses
    		                                                     1,267,947 1,940,637 178,674 81,820 
      loss on sale of research and development inventory
    		                                                         
      general and administrative expenses
    		                                                     696,246 1,034,530 736,924 674,589 
      net income per share
    		                                                     -0.49 -0.7 -0.26 -0.23 
      weighted-average shares outstanding – basic and diluted
    		                                                      4,654,303 4,654,303 2,648,087 
      costs and expenses
    		                                                         
      total costs and expenses
    		                                                        1,217,902 
    Balance Sheets:
    Quarterly
    Annual
      Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31 2011-12-31 2011-09-30 2011-06-30 2011-03-31 2010-12-31 2010-09-30 2010-06-30 2010-03-31 2009-12-31 2009-09-30 2009-03-31 2008-12-31 
                                                                           
        assets
      		                                                                     
        current assets:
      		                                                                     
        cash and cash equivalents
      		138,153,000 87,630,000 61,385,000 90,285,000 71,625,000 103,147,000 86,707,000 88,244,000 45,325,000 51,352,000 74,156,765 62,512,889 69,204,163 86,521,542 34,906,020 52,415,053 69,504,946 51,089,118 34,410,570 42,408,958 61,965,709 55,921,152 59,675,045 75,781,122 101,235,699 26,752,135 48,006,152 73,615,909 16,534,278 22,754,852 42,367,489 55,153,975 26,119,837 43,107,574 13,601,391 25,574,009 8,542,928 9,914,867 7,905,975 12,549,173 8,925,132 10,440,959 9,177,767 7,821,841 16,564,190 17,199,030 13,951,525 17,869,031 26,517,959 26,149,477 5,380,043 7,653,479 10,320,517 12,535,672 10,720,397 12,887,788 14,239,828 8,079 5,909 8,512 16,192 3,100 3,619 12,012 2,934 6,844 9,270 10,108 8,028 
        accounts receivable
      		135,862,000 158,429,000 137,673,000 109,726,000 99,412,000 49,999,000 50,140,000 30,113,000 49,621,000 27,421,000 31,318,680 36,731,612 26,518,495 15,505,048 20,902,385 18,883,847 25,629,625 28,576,857 20,392,621 23,544,594 15,362,030 13,237,290 6,334,536 6,514,165 7,107,834 3,469,919 7,315,481 5,086,663 1,310,404 1,392,441 4,126,794 3,797,194 3,657,602 3,880,154 1,499,809 2,292,274 839,938 1,018,027 1,327,531 826,715 943,950 924,468 1,200,615 522,499 351,443 383,961 562,171 803,513 484,423  335,091 236,918 326,327 39,112 61,897 220,096              
        inventories
      		222,098,000 206,465,000 196,667,000 191,464,000 172,188,000 170,235,000 171,801,000 179,810,000 177,732,000 172,906,000 163,116,105 161,780,063 163,984,873 163,280,047 162,913,633 146,075,459 139,146,311 124,724,091 114,122,873 99,699,743 94,146,200 81,535,599 69,752,528 56,001,348 52,288,803 53,064,734 40,285,339 23,589,750 18,439,912 18,616,169 13,877,434 12,246,968 12,438,802 12,628,181 13,418,971 13,150,733 5,308,492 5,020,146 4,617,734 4,209,326 4,049,239 3,445,773 2,830,814 2,452,896 1,940,934 1,708,763 1,452,556 1,112,601 984,493 1,669,058 1,205,073 915,156 1,007,267 1,265,593 1,009,687 1,203,041 1,175,288             
        prepaid expenses and other current assets
      		15,060,000 7,458,000 6,930,000 8,088,000 8,589,000 8,029,000 9,545,000 5,524,000 3,741,000 5,334,000 5,107,455 5,218,735 4,378,681 5,095,146 5,372,484 5,399,928 5,519,301 4,339,245 5,859,046 5,701,863 5,802,608 3,046,466 3,786,421 4,693,427 4,855,344 2,533,593 1,716,337 1,596,671 2,049,552 1,766,163 2,131,035 2,431,366 2,703,214 2,050,740 2,078,509 2,408,459                                  
        assets held for sale
      		 6,530,000                                 845,389 845,389                                  
        total current assets
      		511,173,000 466,512,000 402,655,000 399,563,000 351,814,000 331,410,000 318,193,000 303,691,000 276,419,000 257,013,000 273,699,005 266,243,299 264,086,212 270,401,783 224,094,522 222,774,287 239,800,183 208,729,311 174,785,110 171,355,158 177,276,547 153,740,507 139,548,530 142,990,062 165,487,680 85,820,381 97,323,309 103,888,993 38,334,146 44,529,625 62,502,752 73,629,503 46,419,455 63,166,649 31,444,069 44,270,864 15,683,204 21,657,138 25,359,589 29,494,236 17,358,209 21,290,404 25,240,341 27,126,916 30,982,138 24,088,015 22,571,543 26,493,609 30,787,513 31,052,449 7,143,625 9,172,513 12,305,553 13,948,138 11,981,577 14,619,089 15,843,577             
        property and equipment
      		65,010,000 65,057,000 69,509,000 57,501,000 57,710,000 54,707,000 53,694,000 54,326,000 55,317,000 53,835,000 54,814,607 56,305,620 57,370,783 58,261,481 56,946,090 54,951,267 53,220,480 50,935,074 48,393,723 46,486,980 44,175,613 41,593,090 39,622,510 37,373,366 35,060,795 31,741,317 30,712,915 29,444,489 29,694,764 30,115,730 30,362,629 30,337,285 30,615,530 30,466,858 29,755,541 28,626,668                   803,709 825,236              
        intangible assets
      		630,000 632,000 491,000 527,000 452,000 460,000 485,000 479,000 321,000 499,000 476,902 655,740 834,577 1,013,415 1,192,254 1,371,092 1,549,930 1,728,768 1,907,607 2,086,445 2,265,283 2,444,121 2,622,959 2,801,797 2,980,636 3,159,474 3,370,708 3,581,943 3,793,177 4,004,412 4,215,646 4,426,881 4,638,115 4,849,350 5,737,175 6,011,003                                  
        goodwill
      		3,530,000 3,530,000 3,530,000 3,530,000 3,530,000 3,530,000 3,530,000 3,530,000 3,530,000 3,530,000 3,529,509 3,529,509 3,529,509 3,529,509 3,529,509 3,529,509 3,529,509 3,529,509 3,529,509 3,529,509 3,529,509 3,529,509 3,529,509 3,529,509 3,529,509 3,529,509 3,529,509 3,529,509 3,529,509 3,529,509 3,529,509 3,529,509 3,529,509 3,529,509 3,529,509 3,529,509                                  
        deferred tax assets
      		69,969,000 73,261,000 74,433,000 79,235,000 80,855,000 84,280,000                                                                
        right-of-use assets
      		6,402,000 6,650,000 9,271,000   8,634,000                                                                
        deposits and other assets
      		8,470,000 8,600,000 8,798,000 9,063,000 8,188,000 5,657,000 5,819,000 5,221,000 5,891,000 4,670,000 6,722,817 6,289,048 4,718,761 4,770,246 4,459,322 3,755,938 2,825,748 4,067,404 3,333,514 2,526,660 2,222,781 2,106,976 1,869,548 4,846,834 3,465,207 2,840,044 2,843,332 2,829,186 2,768,374 1,543,737 530,173 533,422 539,572 510,057 750,693                                   
        total assets
      		665,184,000 624,242,000 568,687,000 558,380,000 510,569,000 488,678,000 390,618,000 376,399,000 350,875,000 329,182,000 348,996,565 343,027,042 340,787,542 348,461,881 300,557,570 296,932,329 308,032,492 276,252,724 238,640,406 232,813,792 235,667,028 207,673,394 189,976,043 191,541,568 210,523,827 127,090,725 137,779,773 143,274,120 78,119,970 88,876,521 106,345,100 117,751,992 91,137,625 108,018,833 72,813,480 84,639,253 17,594,918 23,685,085 27,495,386 31,741,989 19,684,920 23,714,517 27,824,030 29,799,772 33,927,680 27,227,497 25,287,215 27,882,931 31,951,324 31,979,943 8,701,866 10,690,103 13,817,307 15,555,419 13,224,826 15,883,865 17,008,314 8,079 5,909 8,512 16,192 3,100 3,619 12,012 2,934 6,844 9,270 10,108 8,028 
        liabilities and stockholders' equity
      		                                                                     
        current liabilities:
      		                                                                     
        accounts payable
      		20,523,000 22,519,000 24,021,000 29,769,000 20,607,000 20,219,000 16,020,000 14,179,000 17,186,000 15,660,000 10,851,446 12,084,529 12,956,486 13,229,390 25,197,806 11,388,048 14,115,135 12,429,409 17,282,841 6,167,465 12,152,852 11,073,708 7,979,772 6,909,659 9,152,239 9,174,591 8,959,903 6,788,144 5,479,791 5,900,394 5,267,683 3,101,079 5,718,121 5,920,873 9,156,341 4,672,316 3,904,445 2,564,681 2,777,221 3,317,052 2,468,470 2,087,855 2,184,686 1,647,556 1,778,953 1,779,197 2,444,904 2,339,722 2,763,872 2,709,489 1,482,643 1,158,826 1,379,011 1,058,671 890,762 790,869 508,852             
        accrued expenses and other current liabilities
      		48,561,000 40,466,000 28,827,000 43,902,000 31,560,000 33,962,000 27,535,000 27,726,000 33,691,000 32,919,000 29,863,726 28,745,598 22,672,464 24,989,349 18,378,932 15,961,070 16,654,540 17,214,988 14,410,329 11,490,239 8,592,142 8,365,143 8,074,989 5,616,666 4,419,043 4,481,395 4,762,771 2,974,476 2,505,996 3,551,835 4,453,027 3,644,181                                      
        current portion of long-term debt
      		3,281,000 2,813,000 2,344,000                                                                   
        current portion of lease obligations
      		1,176,000 1,096,000 1,298,000 1,127,000 1,188,000 1,218,000 1,193,000 1,142,000 1,093,000 1,045,000 982,891 979,536 956,045 905,369 720,755 579,661 654,003 591,084 501,239 385,858 317,910 365,682 275,988 210,870 193,987 229,073 229,516 223,114 209,506                                         
        liabilities held for sale
      		 2,647,000                                                                    
        total current liabilities
      		73,541,000 69,541,000 56,490,000 74,941,000 53,498,000 55,542,000 44,891,000 44,177,000 53,088,000 49,806,000 41,840,897 41,952,497 36,727,829 39,266,942 44,440,327 28,071,613 31,566,512 30,378,315 32,337,243 18,186,396 21,205,738 19,947,367 16,473,583 12,880,029 13,908,103 14,027,893 15,150,100 10,128,568 8,338,127 9,625,046 9,892,987 6,917,086 9,442,837 9,440,183 13,338,866 15,645,011 12,957,920 11,222,861 9,207,805 5,082,539 4,291,028 4,216,532 4,298,235 3,200,041 3,786,811 4,197,897 4,118,670 3,796,785 4,303,402 3,657,846 2,517,119 2,028,744 2,100,801 1,817,319 1,403,533 1,005,640 1,027,057 5,306 9,809 9,818 5,818 4,818 8,608 12,358 6,708 5,808 9,908 6,858 7,458 
        long-term debt
      		193,584,000 69,330,000 70,084,000                                                                   
        deferred revenue, net of current portion
      		1,369,000 1,405,000 1,440,000 1,476,000 1,512,000 1,547,000 1,583,000 1,619,000 1,654,000 1,690,000 1,725,906 1,761,614 1,797,323 1,833,031 1,868,739 1,904,448 1,940,156 1,975,865 2,011,573 2,047,281 2,082,990 2,118,698 2,154,407 2,190,115 2,225,823 2,261,532 2,297,240 2,332,949 2,368,657 2,404,365 2,440,074 2,475,782 2,511,491 2,547,199 2,582,908 2,618,616 2,654,325 2,690,033                                
        lease obligations, net of current portion
      		6,365,000 6,646,000 9,397,000 9,301,000 8,298,000 8,561,000 8,865,000 9,182,000 9,487,000 9,779,000 9,965,088 10,221,914 10,468,109 10,704,176 10,636,083 10,870,907 7,284,079 7,462,388 6,915,750 7,073,415 6,419,589 4,334,151 2,860,732 2,937,292 1,831,639 1,302,361 1,356,390 1,414,976 1,461,452                                         
        total liabilities
      		274,859,000 146,922,000 137,501,000 160,055,000 137,150,000 139,660,000 158,728,000 188,130,000 197,169,000 193,976,000 197,559,219 196,264,747 195,132,922 196,487,666 200,173,034 182,531,802 181,099,427 135,080,158 135,860,239 121,220,260 123,162,942 119,423,968 118,600,089 114,662,113 114,188,144 100,897,576 101,661,701 96,368,259 68,081,016 69,106,083 69,138,886 65,992,922 68,112,226 67,686,076 59,820,972 56,957,264 28,353,266 28,142,347 27,647,526 27,825,853 23,054,235 22,893,543 22,909,788 20,280,264 20,497,212 21,218,847 16,042,268 15,580,355 16,047,637 10,406,584 9,437,622 8,962,133 7,416,664 6,131,673 1,617,786 1,228,134 1,257,958             
        commitments and contingencies
      		                                                                     
        stockholders' equity
      		                                                                     
        preferred stock, 0.0001 par value...
      		                                                                     
        common stock - voting, 0.0001 par value...
      		24,000 24,000 24,000 24,000 24,000 24,000 24,000 23,000 23,000 23,000 22,596 22,453 22,226 22,182 19,678 19,636 19,635 19,581 13,831 13,187 12,304    8,635                                             
        treasury stock
      		-143,170,000 -32,090,000 -23,188,000                                                                   
        additional paid-in capital
      		649,796,000 671,039,000 665,382,000 660,909,000 655,074,000 657,577,000 652,345,000 644,634,000 642,133,000 641,439,000 640,025,888 637,916,035 630,437,880 629,968,704 566,149,846 565,266,375 564,034,008 553,265,706 498,229,637 489,330,692 471,336,826 428,704,039 392,424,321 381,010,696 380,288,833 290,903,772 290,267,664 289,616,994 239,539,512 236,203,041 235,600,830 235,018,201 191,536,802 191,022,018 150,700,918 150,187,687 102,712,144 102,476,267 102,222,281 101,959,318 88,661,749 88,239,569 87,750,184 87,253,027 86,484,669 75,457,458 75,130,398 74,803,338 74,443,204 74,209,004 47,199,023 46,973,802 46,751,031 46,532,612 46,464,366 46,263,121 46,151,031 156,080 141,080 138,500 138,500 121,500 113,000 113,000 102,000 102,000 96,000 87,000 80,500 
        accumulated deficit
      		-116,325,000 -161,653,000 -211,032,000   -308,583,000 -420,479,000 -456,388,000 -488,450,000 -506,256,000 -488,611,138 -491,176,193 -484,805,486 -478,016,671 -465,784,988 -450,885,484 -437,120,578 -412,112,721 -395,463,301 -377,750,347 -358,845,044 -340,465,103 -321,057,329 -304,139,876 -283,961,785 -264,716,555 -254,155,524 -242,717,065 -229,505,193 -216,437,238 -198,399,251 -183,263,766 -168,515,935 -150,693,793 -137,710,991 -122,508,276 -113,471,781 -106,934,818 -102,375,710 -98,044,471 -92,032,136 -87,419,667 -82,837,014 -77,734,590 -73,055,272 -69,449,737 -65,886,380 -62,501,691 -58,540,446 -52,636,574 -47,935,366 -45,246,419 -40,350,975 -37,109,328 -34,857,791 -31,612,044 -30,405,329             
        total stockholders' equity
      		390,325,000 477,320,000 431,186,000 398,325,000 373,419,000           114,400,527     112,504,086 88,249,426 71,375,954 76,879,455 96,335,683 26,193,149 36,118,072 46,905,861 10,038,954 19,770,438 37,206,214 51,759,070 23,025,399 40,332,757 12,992,508 27,681,989    3,916,136  820,974 4,914,242 9,519,508 13,430,468 6,008,650 9,244,947 12,302,576 15,903,687 21,573,359  1,727,970 6,400,643     2,773 -3,900  10,374 -1,718 -4,989       
        total liabilities and stockholders' equity
      		665,184,000 624,242,000 568,687,000 558,380,000 510,569,000           296,932,329     235,667,028 207,673,394 189,976,043 191,541,568 210,523,827 127,090,725 137,779,773 143,274,120 78,119,970 88,876,521 106,345,100 117,751,992 91,137,625 108,018,833 72,813,480 84,639,253    31,741,989  23,714,517 27,824,030 29,799,772 33,927,680 27,227,497 25,287,215 27,882,931 31,951,324 31,979,943  10,690,103 13,817,307     8,079 5,909 8,512 16,192 3,100 3,619 12,012      
        end of term fee
      		   938,000 1,313,000 1,313,000 1,688,000 1,688,000 1,688,000 1,688,000 1,567,139 1,567,139 1,500,000 1,500,000 1,500,000 1,500,000 1,500,000                                                     
        other non-current liabilities
      		  90,000 2,000 2,000 360,000 375,000 390,000 405,000 419,000 434,647 449,513 338,731 350,454 362,179 373,903 385,628 397,351 232,665 36,151 41,965 54,886 67,808 80,730 93,652 106,574 119,496 132,418 145,340 260,734 277,692 347,898 309,353 105,996 118,318 93,937                                  
        right-to-use assets
      		   8,961,000 8,020,000  8,897,000 9,152,000 9,397,000 9,635,000 9,753,725                                                           
        current portion of deferred revenue
      		   143,000 143,000 143,000 143,000 1,130,000 1,118,000 182,000 142,834 142,834 142,834 142,834 142,834 142,834 142,834 142,834 142,834 142,834 142,834 142,834 142,834 142,834 142,834 142,834 1,197,910 142,834 142,834 142,834 142,834 142,834 142,834 142,834 145,154 145,154 145,154 145,154 145,154 145,154 145,154 145,154 149,326 75,556 75,555 75,556 75,556 75,556 75,556 75,556 75,556 69,259                  
        senior notes payable, net of discount
      		   73,397,000 72,527,000 72,337,000 101,326,000 131,074,000 130,847,000 130,594,000 142,025,542 140,312,070 144,300,930 142,833,063 141,365,706 139,810,931 138,423,052 94,866,239 94,363,008 93,877,017 93,412,660 92,968,866 82,108,633 81,648,187 81,212,090 68,291,163 67,839,162 67,468,637                                          
        liabilities and stockholders’ equity
      		                                                                     
        stockholders’ equity
      		                                                                     
        total stockholders’ equity
      		     349,018,000 231,890,000 188,269,000 153,706,000 135,206,000 151,437,346 146,762,295 145,654,620 151,974,215 100,384,536  126,933,065 141,172,566 102,780,167 111,593,532                                  9,423,746 11,607,040 14,655,731 15,750,356   -1,306    -346 -3,774 1,036  3,250 570 
        total liabilities and stockholders’ equity
      		     488,678,000 390,618,000 376,399,000 350,875,000 329,182,000 348,996,565 343,027,042 340,787,542 348,461,881 300,557,570  308,032,492 276,252,724 238,640,406 232,813,792                                  15,555,419 13,224,826 15,883,865 17,008,314        2,934 6,844 9,270 10,108 8,028 
        right to use assets
      		           10,003,826 10,247,700 10,485,447 10,335,873 10,550,236 7,106,642 7,262,658 6,690,943 6,829,040 6,197,295 4,259,191 2,782,987                                               
        subordinated note payable, net of discount
      		                      14,934,926 14,925,760 14,916,837 14,908,053 14,899,313 14,890,711                                          
        no shares issued and outstanding
      		                                                                     
        104,902,888 and 59,318,355 shares issued and outstanding
      		                     10,490                                                
        common stock, 0.0001 par value...
      		                      8,962 8,635                                              
        assets to be transferred under purchase agreement
      		                             1,153,508 1,204,391 1,295,392 1,395,444 1,496,410 1,596,493 1,698,755                                  
        restricted cash
      		                                1,500,000 1,500,000                 452,004 452,004 452,004 452,004 426,963 426,963 336,963             
        end of term liability, notes payable
      		                             2,760,000 2,760,000 2,760,000 2,760,000 2,760,000 1,790,000 1,790,000 1,790,000 1,790,000 1,790,000 1,790,000 1,432,000 1,432,000 1,432,000 1,432,000 132,500 132,500 132,500 132,500 132,500 132,500 132,500 132,500                  
        obligation to transfer assets under purchase agreement
      		                             12,621,844 12,621,844 12,621,844 12,621,844 12,621,844 12,621,844                                   
        59,318,355 and 46,353,068 shares issued and outstanding
      		                         5,932                                            
        authorized, 59,318,355 and 46,353,068 shares issued and outstanding
      		                          5,932                                           
        authorized, 59,317,806 and 46,353,068 shares issued and outstanding
      		                           5,932                                          
        notes payable, net of discount
      		                            40,885,103 26,440,830 26,153,543 25,878,081 25,616,653 25,368,458 14,534,340 9,360,708                                  
        note payable - related party, net of discount
      		                            14,882,337 14,874,184 14,865,981 14,857,908 14,850,048 14,842,396 14,834,696 14,827,148                                  
        authorized, 46,353,068 shares issued and outstanding
      		                            4,635                                         
        current portion of capital lease obligation
      		                             29,983 29,443 28,992                                      
        capital lease obligation
      		                             119,080 126,765 134,323                                      
        authorized, 46,353,068 and 36,725,499 shares issued and outstanding
      		                             4,635                                        
        common stock - non-voting, 0.0001 par value...
      		                                                                     
        authorized, 0 and 8,591,160 shares issued and outstanding
      		                                                                     
        authorized, 46,351,243 and 36,725,499 shares issued and outstanding
      		                              4,635                                       
        authorized, 46,349,514 and 36,725,499 shares issued and outstanding
      		                               4,635                                      
        accrued expenses
      		                                3,581,882 3,318,478 3,860,121 4,143,812 2,224,719 2,385,356 1,824,798 1,604,500 1,661,922 1,968,384 1,949,419 1,462,561 1,803,434 2,223,639 1,511,010 1,225,999 1,349,931 823,550 911,130 753,143 676,667 747,079 502,594 204,594 508,254 5,306 9,809 9,818 5,818 4,818 8,608 12,358 6,708 5,808 9,908 6,858 7,458 
        other current liabilities
      		                                 57,998 177,250 17,062                                  
        authorized, 36,726,084 and 36,725,499 shares issued and outstanding
      		                                3,673                                     
        authorized, 8,591,160 shares issued and outstanding
      		                                859                                     
        short-term investments
      		                                    245,000 5,390,184 11,026,691 11,270,963 2,694,978 6,368,177 11,764,361 15,930,353 11,512,214 4,652,675 6,319,629 6,313,578 2,203,040 2,935,184                    
        current portion of notes payable
      		                                   6,666,667                                  
        authorized, 36,725,499 and 12,886,741 shares issued and outstanding
      		                                 3,673                                    
        authorized, 8,591,160 and 0 shares issued and outstanding
      		                                 859 859 859                                  
        authorized, 17,202,244 and 12,886,741 shares issued and outstanding
      		                                  1,722                                   
        deposits
      		                                   502,454 29,563 27,163 27,163 27,163 27,163 27,163 27,163 27,163 27,163 27,163 27,163 27,163 27,163 12,577 12,577 12,577 12,577 12,577 12,577 12,577 12,577             
        purchase price payable
      		                                   12,621,844                                  
        authorized, 17,182,321 and 12,886,741 shares issued and outstanding
      		                                   1,719                                  
        prepaid expenses
      		                                    746,846 313,914 481,658 638,059 744,910 111,027 266,784 399,327 613,357 143,586 285,662 394,886 597,598 298,730 223,418 366,960 651,442 107,761 189,596 308,164 428,461             
        property and equipment at cost
      		                                    1,882,151 2,000,784 2,108,634 2,220,590 2,295,994 2,396,950 2,518,638 2,627,693 2,737,762 2,840,698 2,381,200 1,038,927 828,948 765,299 811,398 849,917 801,757    815,197             
        other assets:
      		                                                                     
        total other assets
      		                                    29,563 27,163 27,163 27,163 30,717 27,163 65,051 45,163 207,780 298,784 334,472 350,395 334,863 162,195 746,843 667,673 709,997 827,984 439,540 439,540 349,540             
        liabilities and stockholders' deficiency
      		                                                                     
        current portion of note payable
      		                                    6,666,667 6,111,111 4,444,440                               
        current portion of leasehold improvement loan
      		                                    16,935 16,559 16,192 15,833 15,482 15,139 14,804 14,368 14,154 13,841 13,534 13,234 12,941 12,654 12,373 12,099 11,831 11,569 10,177 10,177 9,951             
        notes payable, net of debt discount
      		                                    10,845,226 12,321,640 13,794,246 18,050,306 14,380,759 14,247,212 14,115,986 13,993,127 14,892,642 14,772,266 9,859,876 9,706,530 9,674,139 4,865,228 4,840,508 4,816,650 4,793,867                 
        deferred rent liability
      		                                    90,476 98,116 105,756 113,396 121,036 128,676 136,316 143,956 151,596 83,214 88,761 94,309 99,857 105,404 110,952 116,500 122,047 127,595 133,142 138,690 144,238             
        leasehold improvement loan, net of current portion
      		                                    15,319 19,697                                
        stockholders' deficiency
      		                                                                     
        preferred stock 0.0001 par value 10,000,000 shares authorized,
      		                                                                     
        and 0 shares issued and outstanding as of march 31, 2017
      		                                                                     
        and december 31, 2016, respectively
      		                                                                     
        common stock 0.0001 par value 75,000,000 shares
      		                                                                     
        authorized, and 12,886,741 shares issued and outstanding
      		                                                                     
        as of march 31, 2017 and december 31, 2016, respectively
      		                                    1,289                                 
        total stockholders' deficiency
      		                                    -10,758,348                                 
        total liabilities and stockholders' deficiency
      		                                    17,594,918                                 
        revenues:
      		                                                                     
        product revenue
      		                                    2,593,163  2,902,155  2,088,178          1,088,452                   
        license and other revenue
      		                                    35,708  35,708  35,708                             
        total revenues
      		                                    2,628,871  2,937,863  2,123,886          1,107,341                   
        operating expenses:
      		                                                                     
        cost of product revenue
      		                                    1,616,287  1,735,771  1,266,421          726,245                   
        research and development
      		                                    1,192,727  1,677,263  2,027,712          1,408,990                   
        plasma centers
      		                                    1,479,476  1,482,586  1,280,419                             
        general and administrative
      		                                    4,277,384  1,779,115  1,707,870          845,301                   
        total operating expenses
      		                                    8,565,874  6,674,735  6,282,422          3,638,312                   
        income from operations
      		                                    -5,937,003  -3,736,872  -4,158,536          -2,530,971                   
        other income:
      		                                                                     
        interest income
      		                                    18,568  11,605  13,508          2,145                   
        interest expense
      		                                    -618,528  -605,972  -467,441          -162,934                   
        other income,net
      		                                    -599,960                                 
        net income
      		                                    -6,536,963  -4,331,239  -4,612,469          -2,688,947                   
        net income per common share,
      		                                                                     
        basic and diluted
      		                                    -0.51  -0.34  -0.43          -0.46                   
        weighted-average shares
      		                                                                     
        outstanding, basic and diluted
      		                                    12,886,741  12,886,741  10,710,587          5,871,002                   
        liabilities and stockholders' (deficiency) equity
      		                                                                     
        stockholders' (deficiency) equity
      		                                                                     
        authorized, and 12,886,741 and 10,713,087 shares issued
      		                                                                     
        and outstanding as of december 31, 2016 and december 31, 2015,
      		                                                                     
        respectively
      		                                     1,289 1,289 1,289                              
        total stockholders' (deficiency) equity
      		                                     -4,457,262 -152,140  -3,369,315          -735,756                   
        total liabilities and stockholders' (deficiency) equity
      		                                     23,685,085 27,495,386            8,701,866                   
        deferred revenue
      		                                      2,725,742 2,761,450 2,797,158 2,832,867 2,887,082 1,467,037 1,485,926 1,504,815 1,523,704 1,542,592 1,561,481 1,580,370 1,599,259 1,624,444                  
        leasehold improvement loan
      		                                      23,977 28,162 32,254 36,256 40,169 44,103 47,737 51,395 54,973 58,471 61,890 65,236 68,507 71,705 74,832 77,890 81,111 83,804 86,663             
        and outstanding as of september 30, 2016 and december 31, 2015,
      		                                                                     
        other income
      		                                      -594,367  -453,933                             
        change in fair value of stock warrants
      		                                                  2,813                   
        loss on extinguishment of debt
      		                                                                     
        and outstanding as of june 30, 2016 and december 31, 2015,
      		                                                                     
        deferred financing costs
      		                                        3,554  37,888 18,000 180,617 271,621 307,309 323,232 307,700 149,618 282,262 203,092 245,416 363,403                
        authorized, and 10,713,087 shares issued
      		                                                                     
        and outstanding
      		                                        1,072     929 929 929                      
        total liabilities and stockholders'
      		                                                                     
        equity
      		                                        19,684,920                             
        accrued interest
      		                                            114,715 105,664 73,666 142,274 101,102 36,597 35,417 35,417 33,292                 
        warrant liability
      		                                             476,760 263,784 249,168 214,368  168,777 171,590 192,617 229,345                
        authorized, and 10,713,087 and 9,291,823 shares issued
      		                                                                     
        and outstanding as of december 31, 2015 and december 31,
      		                                                                     
        2014, respectively
      		                                         1,072 1,072 1,071 1,071                         
        and outstanding as of september 30, 2015 and december, 31
      		                                                                     
        authorized, and 10,705,573 and 9,291,823 shares issued
      		                                                                     
        and outstanding as of june 30, 2015 and december 31,
      		                                                                     
        and outstanding as of march 31, 2015, and december, 31
      		                                                                     
        authorized, and 9,291,823 shares issued
      		                                                                     
        and outstanding at march 31, 2014 and december 31, 2013
      		                                                929                     
        authorized, 9,291,823 and 5,871,002 shares issued
      		                                                                     
        and outstanding at december 31, 2013 and 2012, respectively
      		                                                 929                    
        common stock .0001 par value 75,000,000 shares
      		                                                                     
        authorized, 5,871,002 shares issued and outstanding
      		                                                  587 587 587                 
        license revenue
      		                                                  18,889                   
        plasma center
      		                                                  657,776                   
        total other income
      		                                                  -157,976                   
        income before income taxes
      		                                                  -2,688,947                   
        state income tax benefit
      		                                                                     
        stockholders' equity:
      		                                                                     
        end of term liability, note payable
      		                                                    132,500 106,000                
        common stock .0001 par value at march 31, 2013 and
      		                                                                     
        december 31, 2012, respectively; 75,000,000 shares
      		                                                                     
        property and equipment, at cost
      		                                                     779,297                
        notes payable - related parties
      		                                                                     
        note payable, net of debt discount
      		                                                     3,773,524                
        preferred stock - 0.001 par value...
      		                                                                     
        common stock - 0.0001 and 0.001 par value at december 31, 2012 and 2011, respectively; 75,000,000 and 6,500,000 shares authorized, 4,622,831 and 408,589 shares issued and outstanding at december 31, 2012 and 2011, respectively
      		                                                     462                
        current assets
      		                                                                     
        other assets
      		                                                                     
        equity issuance costs
      		                                                                     
        current liabilities
      		                                                                     
        notes payable – related parties
      		                                                                     
        preferred stock - 0.001 par value: 10,000,000 and 8,221,678 shares authorized, 0 and 8,221,678 shares issued and outstanding with a liquidation preference of 0 and 31,959,545 at september 30, 2012 and december 31, 2011, respectively
      		                                                                     
        common stock - 0.0001 and 0.001 par value: 75,000,000 and 6,500,000 authorized, 4,654,303 and 408,589 shares issued and outstanding at september 30, 2012 and december 31, 2011, respectively
      		                                                      465               
        preferred stock - 0.001 par value: 10,000,000 and 8,221,678 shares authorized, 0 and 8,221,678 shares issued and outstanding with a liquidation preference of 0 and 31,959,545 at june 30, 2012 and december 31, 2011, respectively
      		                                                                     
        common stock - 0.001 par value: 75,000,000 and 6,500,000 authorized, 4,654,303 and 408,589 shares issued and outstanding at june 30, 2012 and december 31, 2011, respectively
      		                                                       4,654              
        preferred stock - 0.001 par value: 10,000,000 and 8,221,678 shares authorized, 0 and 8,221,678 shares issued and outstanding with a liquidation preference of 0 and 31,959,545 at march 31, 2012 and december 31, 2011, respectively
      		                                                                     
        common stock - 0.001 par value: 75,000,000 and 6,500,000 authorized, 4,654,303 and 408,589 shares issued and outstanding at march 31, 2012 and december 31, 2011, respectively
      		                                                        4,654             
        preferred stock, .0001 par value...
      		                                                                     
        common stock, .0001 par value...
      		                                                         250 250 250 250 250 250 250 250 250 250 250 250 
        deficit accumulated during the development stage
      		                                                         -153,557 -145,230  -128,468 -123,468 -118,239  -106,024 -101,214 -96,888 -84,000 -80,180 
        preferred stock; .0001 par value...
      		                                                                     
        deficit accumulated during the development period
      		                                                           -140,056    -113,596      
        liabilities and stockholders’ deficiency
      		                                                                     
        stockholders’ deficiency
      		                                                                     
        total stockholders’ deficiency
      		                                                                  -638   
      Cashflow Statements:
      Quarterly
      Annual
        Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31 2009-06-02 2009-03-31 
                                                                   
          cash flows from operating activities:
        		                                                           
          net income
        		45,328,000 49,379,000 36,429,000 34,218,000 26,904,000 111,896,000 35,909,000 32,062,000 17,806,000                                                -597,314 -3,818 -3,820 
          adjustments to reconcile net income to net
        		                                                           
          cash from operating activities:
        		                                                           
          depreciation and amortization
        		1,839,000 2,046,000 2,023,000 2,058,000 1,969,000 1,944,000 1,940,000 2,047,000 2,114,000 2,108,950 2,092,508 2,097,577 2,032,965 1,936,877 1,861,992 1,724,283 1,590,217 1,517,716 1,422,164 1,325,994 1,229,628 1,232,509 1,035,293 885,652 788,838 828,598 818,128 806,092 805,330 923,902 847,057 845,898 829,541 1,461,036 836,071 277,132 118,062 117,874 117,308 116,001 118,393 117,192 117,930 117,577 117,122 96,790 54,199 48,564 48,299 51,558 54,887 60,575 43,613 41,346 48,896 46,112 45,735   
          gain on sale of plasma centers
        		                                                           
          loss on disposal of fixed assets
        		42,000     74,000 8,000 1,000 23,000 71,053 92,851 0 18,096 418,128 5,770 638 2,000 140,282 2,344 77,354 781 69,219 8,960 2,542 976    391 108,990 10,741   5,989 0 0 4,155                       
          deferred income tax provision
        		3,292,000 1,172,000 4,803,000 1,620,000 3,425,000                                                       
          stock-based compensation
        		6,329,000 5,392,000 5,047,000 4,963,000 4,624,000 5,433,000 3,179,000 2,863,000 2,141,000 1,745,155 1,694,641 1,637,038 1,110,166 1,068,602 1,313,494 1,191,047 1,641,388 1,213,393 688,274 805,189 781,397 688,182 774,784 715,608 676,548 636,108 650,670 726,736 637,263 595,532 577,581 535,391 514,784 508,689 505,730 311,363 235,877 253,986 262,963 310,945 422,180 489,385 447,932 386,661 387,069 327,060 327,060 360,134 234,200 221,759 225,221 222,771 218,544       
          amortization of debt discount
        		191,000 197,000 170,000 160,000 190,000 219,000 252,000 227,000 253,000 698,210 721,040 686,861 487,889 493,542 981,066 342,219 584,842 503,231 485,991 464,357 443,794 438,084 469,612 445,021 429,711 460,741 379,126 95,714 244,767 295,490 283,536 269,288 255,847 225,999 181,179 184,136 190,253 194,065 188,380 160,951 133,547 131,226 127,547 48,591 46,271 38,196 34,112 32,391 28,498 24,720 23,858 22,782 20,344       
          amortization of license revenue
        		     -36,000 -36,000 -35,000 -36,000 -35,875 -35,708 -35,709 -35,708 -35,709 -35,708 -35,709 -35,708 -35,709 -35,708 -35,709 -35,708 -35,709 -35,708 -35,709 -35,708 -35,709 -35,708 -35,709 -35,708 -35,709 -35,708 -35,709 -35,708 -35,709 -35,708 -35,709 -35,708  -35,708 -35,708 -35,709  -31,184 -18,889 -18,889 -18,889 -18,889 -18,889 -18,889 -18,889 -18,889         
          changes in operating assets and liabilities:
        		                                                           
          accounts receivable
        		22,567,000     141,000 -20,027,000 19,508,000 -22,200,000 3,897,632 5,412,930 -10,213,116 -11,013,446 5,397,337 -2,018,539 6,745,778 2,947,233 -8,184,236 3,151,973 -8,182,564 -2,124,740 -6,902,754 179,629 593,669 -3,637,915 3,845,562 -2,228,818 -3,776,259 82,037 2,734,353 -329,600 -139,592 222,552 -2,380,345 792,464 -1,452,335 178,089 309,504 -500,816 117,235 -19,482 276,147 -678,116 -171,056 32,518 178,210 241,342 -319,090 -484,423 335,091 -98,173 89,409 -287,215 22,785 158,199     
          inventories
        		     1,566,000 8,009,000 -2,078,000 -4,826,000 -9,789,942 -1,336,042 2,204,810 -704,826 -366,414 -16,838,175 -6,929,149 -14,422,219 -10,601,217 -14,423,128 -5,553,543 -12,610,601 -11,783,070 -13,751,180 -3,712,546 775,932 -12,779,396 -16,695,588 -5,149,838 -25,310 -4,738,735 -1,630,466 191,834 189,379 790,790 -268,238 355,112 -288,346 -402,412 -408,408 -160,087 -603,466 -614,959 -377,918 -511,962 -232,171 -256,206 -339,955 -128,109 684,566 -463,985 -289,917 92,111 258,326 -255,906 193,354     
          prepaid expenses and other current assets
        		     1,516,000 -4,021,000 -1,783,000 1,593,000 -226,691 111,281 -840,055 716,465 277,338 27,445 119,373 -1,180,056 1,519,801 -157,183 100,745 -2,756,142 739,955 907,006 161,917 -2,321,751 -817,255 -119,666 452,881 -289,134 -460,214 300,331 271,848 -652,474                           
          deposits and other assets
        		379,000 540,000   120,000 426,000 -343,000 914,000 -982,000 2,300,849 -183,668 -1,326,413 289,232 -73,288 -489,021 -712,895 1,397,672 -961,790 -668,758 -164,375 19,718 -122,414 208,860 -203,663 -79,532 3,287 -14,145 -60,812 179,644                               
          accounts payable
        		 -2,203,000 -4,876,000 9,267,000 142,000 3,942,000 1,618,000 -1,857,000 447,000 4,993,769 -9,907 -871,958 -272,904 -11,968,415 13,809,757 -2,727,085 1,685,724 -4,853,432 11,115,376 -5,985,388 1,079,144 3,093,935 1,070,112 -2,242,576 -22,356 214,689 2,171,758 1,308,354 -420,601 632,710 2,166,602 -2,617,038 -202,754 -2,416,030 3,465,071 423,261 1,339,764 -212,540 -344,727 657,032 377,061 -3,241 617,405 -235,640 -69,866 -672,025 104,013 -424,150 54,383 1,185,008 323,817 -220,185 320,340 167,909 99,893     
          accrued expenses
        		5,105,000 10,639,000    6,426,000 -191,000 -5,965,000 772,000 2,655,622 136,001 6,092,192 -1,353,815 6,867,379 2,128,814 313,905 -1,775,526 2,815,121 2,545,686 3,823,577 -843,043 784,343 2,218,177 2,329,886 -1,930,591 -520,010 1,855,952 232,952 -762,541 -606,019 458,118 466,245 88,640 -663,217 -106,440 1,544,777 -160,637 560,558 220,298 -57,422 -306,462 18,965 555,872 -259,888 -514,564 680,570 314,835 -169,849 526,381 -19,259 89,666 76,476 -70,412 174,952 323,001     
          other current and non-current liabilities
        		     -294,000 -1,269,000 -258,000 677,000 -229,655 -268,336 -105,458 -187,551 -136,823 -110,424 -143,927 -111,064 111,028 173,536 -32,571 -33,413 -22,145 -20,179 -46,185 -45,882 -52,598 -46,887 -20,587 -70,442 -16,959 -59,361 43,018 207,736                           
          net cash from operating activities
        		58,249,000 35,639,000 13,293,000   50,216,000 25,028,000 45,646,000 -2,218,000 17,595,952 11,985,078 -6,058,756 -14,722,274 -7,379,315 -13,284,761 -12,830,768 -26,013,413 -33,465,232 -13,412,387 -32,262,237 -33,229,126 -32,219,436 -23,852,087 -21,284,475 -24,646,960 -19,652,036 -23,630,332 -18,623,952 -14,287,184 -18,793,124 -12,543,405 -14,908,039 -16,434,114 -13,358,629 -9,739,371 -8,775,348 -5,398,426 -3,613,678 -4,683,188 -4,804,177 -5,167,930 -4,078,209 -2,673,053 -4,446,367 -4,220,775 -2,902,433 -2,465,868 -4,296,279 -5,040,330 -2,959,763 -2,225,662 -2,626,958 -3,074,771 -1,807,050 -2,101,188 -996,858 -1,998,699 -5,418 -4,420 
          capital expenditures
        		0 0 0   -2,757,000 -1,056,000 -2,066,000 -2,347,000 -1,197,214 -756,557 -872,633 -1,944,596 -3,748,521 -3,380,481 -3,940,084 -2,842,085 -3,675,854 -2,788,669 -4,475,574 -2,571,161 -3,598,321 -2,885,075 -4,168,408 -2,074,876 -1,594,296 -1,971,867 -135,222 -110,453 -819,006 -230,219 -497,129 -549,246 -2,009,871 -569,900 -92,973 -3,584 -10,024 -5,352 -40,597 -17,437 4,496 -8,875 -7,508 -14,186 -556,288 -1,396,472 -258,543 -111,948 -5,459 -16,367 -108,735 -66,074 0 0 0 0 0 0 
          free cash flows
        		58,249,000 35,639,000 13,293,000   47,459,000 23,972,000 43,580,000 -4,565,000 16,398,738 11,228,521 -6,931,389 -16,666,870 -11,127,836 -16,665,242 -16,770,852 -28,855,498 -37,141,086 -16,201,056 -36,737,811 -35,800,287 -35,817,757 -26,737,162 -25,452,883 -26,721,836 -21,246,332 -25,602,199 -18,759,174 -14,397,637 -19,612,130 -12,773,624 -15,405,168 -16,983,360 -15,368,500 -10,309,271 -8,868,321 -5,402,010 -3,623,702 -4,688,540 -4,844,774 -5,185,367 -4,073,713 -2,681,928 -4,453,875 -4,234,961 -3,458,721 -3,862,340 -4,554,822 -5,152,278 -2,965,222 -2,242,029 -2,735,693 -3,140,845 -1,807,050 -2,101,188 -996,858 -1,998,699 -5,418 -4,420 
          cash flows from investing activities:
        		                                                           
          purchase of property and equipment
        		     -2,757,000 -1,056,000 -2,066,000 -2,347,000 -1,197,214 -756,557 -872,633 -1,944,596 -3,748,521 -3,380,481 -3,940,084 -2,842,085 -3,675,854 -2,788,669 -4,475,574 -2,571,161 -3,598,321 -2,885,075 -4,168,408 -2,074,876 -1,594,296 -1,971,867 -135,222 -110,453 -819,006 -230,219 -497,129 -549,246 -2,009,871 -569,900 -92,973 -3,584 -10,024 -5,352 -40,597 -17,437 4,496 -8,875 -7,508 -14,186 -556,288 -1,396,472 -258,543 -111,948 -5,459 -16,367 -108,735 -66,074       
          acquisition of intangible assets
        		     7,000 -42,000 -299,000 -15,000                                                   
          proceeds on the sales of assets held for sale
        		5,000,000                                                           
          net cash from investing activities
        		2,404,000     -2,750,000 -1,098,000 -2,365,000 -2,362,000 -1,407,214 -756,557 -872,633 -1,944,596 -3,748,521 -3,380,481 -3,940,084 -2,842,085 -3,675,854 -2,788,669 -4,475,574 -2,571,161 -3,598,321 -2,885,075 -4,168,408 -2,072,876 -1,594,296 -1,971,867 -135,222 -110,453 -819,006 -230,219 -497,129 -549,246 -2,009,871 -569,900 12,652,027 5,141,600 5,626,483 238,920 -8,616,582 3,655,762 5,400,680 4,157,117 -4,425,647 -6,873,725 1,110,666 -1,402,524 -4,369,080 620,195 -2,940,643 -16,367 -108,735 -66,074 -35,332 -27,370     
          cash flows from financing activities:
        		                                                           
          jpm term loan payments
        		                                                           
          jpm revolving facility proceeds
        		125,000,000                                                           
          taxes paid on vested restricted stock units
        		     -644,000 -1,158,000 -693,000 -2,476,000 -340,450 -208,638 -224,966 -640,946 -2,067,543 -429,982 -309,948 -91,367 0 -2,287 0 -59,311                                       
          net proceeds from the exercise of stock options
        		588,000 430,000 389,000 2,064,000 101,000 443,000 5,691,000 331,000 1,029,000 8,461                                                  
          acquisition of treasury stock
        		                                                           
          net cash from financing activities
        		     -31,026,000 -25,467,000 -362,000 -1,447,000 -38,993,961 415,355 240,115 -650,509 62,743,358 -843,791 -319,041 47,271,326 53,819,634 8,202,668 17,181,060 41,844,844 32,063,864 10,631,085 -1,694 101,203,400 -7,685 -7,558 75,840,805 4,177,063 -507 -12,862 42,939,306 -4,377 50,374,683 -1,663,347 13,154,402 -1,115,113 -3,913 -198,930 17,044,800 -3,659 -59,279 -128,138 129,665 10,459,660 5,039,272 -49,114 16,431 4,788,617 26,669,840 -31,407 68,655 925,690 3,657,657 -38,833 -299,031 16,150,756 6,000 6,500 
          net increase in cash and cash equivalents
        		50,523,000     16,440,000 -1,537,000     -6,691,274 -17,317,379   -17,089,893 18,415,828  -7,998,388 -19,556,751 6,044,557 -3,753,893 -16,106,077 -25,454,577 74,483,564  -25,609,757 57,081,631 -10,220,574 -19,612,637 -12,786,486   35,006,183 -11,972,618                   1,815,275 -2,167,391 -1,352,040 14,152,057 582 2,080 
          cash and cash equivalents - beginning of period
        		87,630,000  0 0 103,147,000  0 0 51,352,000  0 0 86,521,542  0    0 0 55,921,152              0 0 9,914,867  0 0 10,440,959  0 0 17,199,030  0 0 26,149,477  0 0 12,535,672       
          cash and cash equivalents - end of period
        		138,153,000  -28,900,000 18,660,000 71,625,000  -1,537,000 42,919,000 45,325,000  11,643,876 -6,691,274 69,204,163  -17,509,033 -17,089,893 69,504,946  -7,998,388 -19,556,751 61,965,709  -16,106,077 -25,454,577 101,235,699          -11,972,618 17,031,081 8,542,928  -4,643,198 3,624,041 8,925,132  1,355,926 -8,742,349 16,564,190  -3,917,506 -8,648,928 26,517,959  -2,273,436 -2,667,038 10,320,517       
          adjustments to reconcile net income to net cash from operating activities:
        		                                                           
          interest paid in kind
        		         877,408 992,432 986,182 979,978 973,814 978,272                                             
          loss on extinguishment of debt
        		 0 2,177,000           0 0 0 6,669,941         0 0 0 9,962,495             0 0                 
          deposit received on net assets held for sale
        		                                                           
          ares term loan payments
        		                                                           
          ares revolving facility payments
        		                                                           
          ares revolving facility proceeds
        		 0                                                          
          jpm term loan proceeds
        		 0                                                          
          prepayment penalties on repayment of debt
        		                                                           
          proceeds from issuance of note payable
        		             0 0 0 151,750,000     15,000,000 0 0 12,500,000 0 0 27,500,000 45,000,000                               
          payments on finance lease obligations
        		         -972 0 -6,465 -9,563 -9,403 -9,247 -9,093 -8,941 -8,792 -8,647 -8,500 -8,360 -8,220 -8,083 -7,949 -7,816 -7,685 -7,558 -7,432 -7,308                               
          debt issuance costs
        		                                             0 0 28,186 -58,326           
          payment of end of term fee
        		                          0 0 -2,760,000                               
          payment of deferred financing fees
        		             0 -404,562 0 -2,378,366                                           
          cash and cash equivalents - beginning of year
        		                51,089,118                                           
          cash and cash equivalents - end of year
        		                                                           
          principal payments on term loan
        		                                                           
          proceeds from issuance on revolver
        		                                                           
          adjustments to reconcile net income to net cash provided used in operating activities:
        		                                                           
          net decrease in cash and cash equivalents
        		        -6,027,000                        -16,987,737    -1,371,939 2,008,892   -1,515,827 1,263,192 1,355,926    -3,917,506             
          deferred income tax benefit
        		                                                           
          principal payments on notes payable
        		             0 0 0 -100,000,000         0 0 0 -30,000,000     -15,555,556 -1,666,666                         
          proceeds from issuance of common stock, net of offering expenses
        		                 53,828,426 8,213,602 17,189,560 41,912,515     0 0   0 -1,280                             
          repayment of notes payable
        		                                                           
          payment of debt refinancing fees
        		             0 0 0 -2,000,000         0 0 0 -6,499,867                               
          net loss
        		          2,565,055 -6,370,707 -6,788,815 -12,231,683 -14,899,504 -13,764,906 -25,007,857 -16,649,420 -17,712,954 -18,905,303 -18,379,941 -19,407,774 -16,917,453 -20,178,091 -19,245,230 -10,561,031 -11,438,459 -13,211,872 -13,067,955 -18,037,987 -15,135,485 -14,747,831 -17,822,142 -12,982,802 -15,202,715 -9,036,495 -6,536,963 -4,559,108 -4,331,239 -6,012,335 -4,612,469 -4,582,653 -5,102,424 -4,679,318 -3,605,535 -3,563,357 -3,384,689 -3,961,245 -5,903,872 -4,701,208 -2,688,947 -4,895,444 -3,241,647 -2,251,537 -3,245,747     
          adjustments to reconcile net loss to net cash from operating activities:
        		                                                           
          proceeds from the exercise of stock options
        		                     0 0 6,255 7,177 0 0   6,679    0                          
          gain on extinguishment of debt
        		                                                           
          proceeds from the sale of property and equipment
        		                     0 0 0 2,000                                   
          net (decrease) increase in cash and cash equivalents
        		                                                           
          gain on transfer of plasma center assets
        		                                                           
          payment of end of end of term fee
        		                                                           
          payment of debt issuance costs
        		                         0 0 -123,899 -1,555,762     -1,475,331 0                         
          cash and cash equivalents, including restricted cash - beginning of year
        		                                                           
          adjustments to reconcile net loss to net
        		                                                           
          deferred revenue
        		                                         0        0 0         
          proceeds from the issuance of common stock, net of offering expenses
        		                      10,639,168 0 88,704,039                                   
          cash and cash equivalents, including restricted cash - beginning of period
        		                      0 0 26,752,135  0 0 26,754,852  0 0 48,607,574                           
          changes in operating assets and liabilities, net of acquisition:
        		                                                           
          payments of leasehold improvement loan
        		                             0 -10,844 -4,476 -4,377 -4,280 -4,185 -4,092 -4,002 -3,913 -3,826 -3,741 -3,659 -3,578 -3,498 -3,420 -3,345 -3,271 -3,198 -3,128 -3,057 -2,990 -2,924 -2,859 -2,796 -1,829 -2,693 -2,633 -2,575   
          cash and cash equivalents, including restricted cash - end of year
        		                                                           
          loss on disposal of property and equipment
        		                          18,229                                 
          gain on transfer of plasma assets
        		                          0 -1 -11,527,420                               
          cash and cash equivalents, including restricted cash - end of period
        		                          -25,609,757 57,081,631 16,534,278  -12,786,486 27,534,138 31,619,837                           
          asset impairment charge
        		                                                           
          sales of short-term investments
        		                                 0 0 245,000 5,145,184    3,673,199                   
          cash acquired in acquisition transaction
        		                                 0 0                         
          proceeds from issuance of related party note payable
        		                                 0 0                         
          payments on capital lease obligations
        		                             -7,186 -7,066                             
          other assets
        		                              3,249 6,150 -29,515 240,636 -248,239 -472,891 -2,400         0 0 -20,689 6,103 460,648 -8,644 -54,314 195,361  0     
          other current liabilities
        		                                 -8,041 11,505                         
          purchase of short-term investments
        		                                      244,272   5,396,184 4,165,992 -4,418,139 -6,859,539 1,666,954 -6,052             
          cash and cash equivalents - end of year, including restricted cash
        		                                                           
          prepaid expenses
        		                                  329,949 -866,059 -432,932 167,744 156,401 106,851 -633,883 155,757 132,543 214,030 -469,771 142,076 109,223 202,713 -298,868 -75,312 143,542 284,482 -543,681 81,835 118,568     
          deferred rent liability
        		                                    -7,640 -7,640 -7,640 -7,640 -7,640 -7,640 -7,640 -7,640 68,382 -5,547 -5,548 -5,547 -5,548 -5,548 -5,548 -5,547 -5,548 -5,548 -5,547     
          principal payments on note payable
        		                                    -1,111,111                       
          supplemental information:
        		                                                           
          cash paid for interest
        		                                    424,470 425,818 422,947 353,247 328,223 319,207 217,329 465,874 324,378 223,822 225,162 230,293 106,250 107,431 108,611 105,305 61,389  0 0 3,820   
          supplemental disclosure of noncash financing activities:
        		                                                           
          accrued equity issuance costs
        		                                       168,646 3,554  -116,115 -65,619 219,622 38,375 -28,652   -26,483      -254,393 279,394   
          warrant liability
        		                                         0 0 0 -67,860 30,160 14,616 34,800 -5,220 17,278 -2,813 -21,027 -36,728       
          amortization of deferred financing costs
        		                                         0 0 16,353 23,364 31,520 33,187 31,515 29,555 27,196 26,278 25,124 20,640       
          payment-in-kind interest
        		                                         0 0 50,432 74,104 57,011 50,261 49,468 19,505           
          amortization of license and other revenue
        		                                                           
          purchases of short-term investments
        		                                                           
          redemptions of short-term investments
        		                                                           
          proceeds from oxford note payable
        		                                     0 0   0 0                 
          proceeds from issuance of common stock
        		                                     0 1,072,259   0 -136,003 -69,622 10,463,005               
          proceeds from stock options exercised
        		                                         1                  
          repayment of hercules note payable
        		                                         0 0                 
          prepayment penalty of early extinguishment of note payable
        		                                         0                  
          payment of hercules end of term fee
        		                                         0 0                 
          equity issuance costs
        		                                     0        42,543 -45,916             
          reclassification of equity issuance costs to additional paid-in capital
        		                                            11,999          0 0 421,077   
          warrants issued in connection with note payable
        		                                     0 0   0 0   182,816 0 0 219,588           
          end of term liability in connection with note payable
        		                                     0    0                  
          elimination of warrant liability
        		                                         0 0 0 408,900               
          accrued interest
        		                                         0 0 -114,715 9,051 31,998 365 -8,296 45,000 1,180 0 2,125 33,292  0     
          reclassification of equity issuance costs
        		                                          0                 
          non-cash deferred financing fees
        		                                          -33,176                 
          accrued debt issuance costs
        		                                                           
          noncash deferred financing fees
        		                                                           
          end of term liability for oxford note payable
        		                                                           
          proceeds from hercules note payable, net of fees
        		                                             5,000,000 0 0 4,850,000           
          prepayment penalty of early extinguishment of hercules note payable
        		                                                           
          debt issuance costs of oxford note payable
        		                                                           
          proceeds from short-term investments
        		                                                           
          net increase in cash and
        		                                                           
          cash equivalents
        		                                            -634,840    368,482 20,769,434 -2,273,436 -2,667,038 -2,215,155       
          net proceeds from issuance of common stock
        		                                                           
          end of term liability for hercules note payable
        		                                                 0 0 0 26,500       
          proceeds from sale of short-term investments
        		                                                732,143           
          payment of equity issuance costs
        		                                                 -357,990   -71,514 -71,514 -36,140 -296,398 -933,957   
          non-cash interest expense related to notes payable
        		                                                           
          loss on sale of equipment
        		                                                           
          short-term investments
        		                                                           
          proceeds from hercules note payable
        		                                                 0 0         
          repurchase of common stock
        		                                                           
          repayments of notes payable
        		                                                           
          net increasein cash and
        		                                                           
          conversion of notes payable and interest in private placement
        		                                                           
          stock retained by stockholders of shell company
        		                                                     0      
          proceeds from issuance of common stock, net of note
        		                                                           
          payable conversion
        		                                                           
          payments on notes payable
        		                                                      0 0 -200,000   
          conversion of notes payable and accrued interest into common stock
        		                                                      0 0 262,740   
          stock issued to shell company
        		                                                       0 53   
          decrease in:
        		                                                           
          increase in:
        		                                                           
          changes in assets and liabilities:
        		                                                           
          proceeds from hercules debt note payable
        		                                                    1,000,000       
          conversion of notes payable and accrued interest into
        		                                                           
          common stock
        		                                                           
          reclassification of equity issuance costs to additional
        		                                                           
          paid in capital
        		                                                           
          amortization of debt discount and beneficial conversion charge
        		                                                           
          noncash interest expense related to notes payable
        		                                                           
          loss on sale of inventory
        		                                                           
          loss on disposal of equipment
        		                                                           
          restricted cash
        		                                                           
          cash flows from investing activities purchase of equipment
        		                                                           
          cash flows from financing activities
        		                                                           
          proceeds from the issuance of common stock, net of note payable conversion
        		                                                           
          proceeds from note payable, net of fees
        		                                                           
          proceeds from convertible notes payable
        		                                                           
          cash and cash equivalents, beginning of year
        		                                                           
          cash and cash equivalents, end of year
        		                                                           
          interest paid
        		                                                           
          supplemental disclosures:
        		                                                           
          noncash financing activities:
        		                                                           
          preferred stock issued upon note payable and interest conversion
        		                                                           
          equity issuance costs, accrued and not paid
        		                                                           
          issuance of common stock through the cashless exercise of warrants
        		                                                           
          end of term liability for note payable
        		                                                           
          loss on sale of research and development inventory
        		                                                           
          stock based compensation
        		                                                      208,195 154,095 46,254   
          purchase of equipment
        		                                                      -27,370     
          proceeds from issuance of common stock, net of note payable conversion
        		                                                      0 0 17,287,288   
          cash and cash equivalents – beginning of period
        		                                                      0 0 87,771   
          cash and cash equivalents – end of period
        		                                                      -2,167,391 -1,352,040 14,239,828   
          loss-on sale of research and development inventory
        		                                                           
          increase in inventories
        		                                                        -27,943   
          increase in accounts receivable
        		                                                           
          increase in prepaid expenses
        		                                                        -369,217   
          decrease in other assets
        		                                                           
          increase in accounts payable
        		                                                        -794,562   
          increase in accrued expenses
        		                                                        -298,064 -1,600 -600 
          increase in accrued interest
        		                                                        1,959   
          decrease in deferred rent liability
        		                                                        -5,547   
          1.
        		                                                           
          cash flows from operating activities
        		                                                           
          changes in operating assets and liabilities
        		                                                           
          proceeds received from subscribers of
        		                                                           
          contributed capital
        		                                                         6,000 6,500 
          cash and cash equivalents at beginning of period
        		                                                         8,688 0 
          cash and cash equivalents at end of period
        		                                                         9,270 2,080 
          supplemental disclosure of cash flows information
        		                                                           
          income taxes
        		                                                           
          exhibit
        		                                                           
          31.1
        		                                                           
          31.2
        		                                                           
          32.1
        		                                                           
          32.2
        		                                                           
          proceeds received from subscribers of common stock
        		                                                           
          10.1